Partner Research Centers:


Center for Neurodegenerative Disease Research

Leslie M. Shaw

faculty photo
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Co-Director, Alzheimer's Disease Neuroimaging, Initiative Biomarker Core Laboratory, University of Pennsylvania
Department: Pathology and Laboratory Medicine

Contact information
Hospital of the University of Pennsylvania
7.103 Founders Pavilion 3400 Spruce Street
Philadelphia, PA 19104
Office: (215) 662-6575
Fax: (215) 662-7529
Education:
B.S. (Cum Laude, Chemistry)
LeMoyne College, Syracuse, New York, 1962.
Ph.D. (Biochemistry)
S.U.N.Y. at Upstate Medical Center, 1968.
Post-Graduate Training
NIH Post doctoral Fellowship Department of Molecular Biology, The Johns Hopkins University, Baltimore, MD, 1968-1970.
Fellow, Neuroscience Research Program, 1969-1969.
NIH Postdoctoral Fellowship, William Pepper Laboratories, Hospital of the University of Pennsylvania, Philadelphia, PA, 1970-1972.
Certifications
American Board of Clinical Chemistry, 1973.
American Board of Clinical Chemistry in Toxicological Chemistry, 1990.
USC School of Medicine, Laboratory of Applied Pharmacokinetics , 1995.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Development, validation and implementation of neurodegenerative diseases biomarkers in cerebrospinal fluid and plasma into treatment trials and clinical studies (eg, ADNI study; PPMI study). These studies include the use of manual and highly automated immunoassays and for amyloid beta(1-42) and for total tau the use of high sensitivity UPLC/tandem mass spectrometry. Multi-modal statistical analyses of these study data to address several questions including the diagnostic utilities of these biomarkers; assessments of the longitudinal trajectories of these biomarkers in AD, MCI and cognitively normal controls to assess the neuropathological changes over time in these individuals.

Description of Clinical Expertise

Measurement and interpretation of the toxicokinetics of drugs and toxins in patients affected by them. Interpretation of the pharmacokinetics of immunosuppressant maintenance medications in transplant patients.

Description of Other Expertise

Development and implementation of mass spectrometry-based methods for measuring small molecules of clinical utility including therapeutic drugs, toxins and special chemistry tests including 25-OH vitamin D.

Selected Publications

Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, Lifke V, Corradini V, Eichenlaub U, Batrla R, Buck K, Zink K, Rabe C, Blennow K, Shaw LM. : CSF biomarkers of Alzheimer’s disease concord with amyloid-B PET and predict clinical progression: A study of fully-automated immunoassays in BioFINDER and ADNI cohorts. Alz and Dementia - In Press. 2018 - In Press.

Phillips JS, Da Re F, Dratch L, Xie SX, Irwin DJ, McMillan CT, Vaishnavi SN, Ferrarese C, Lee EB, Shaw LM, Trojanowski JQ, Wolk DA, Grossman M. : Neocortical origin and progression of gray matter atrophy in nonamnestic Alzheimer's disease. Neurobiology of Aging. 63, 2018 - In Press Notes: Available online ahead of print - November 21, 2017. https://doi.org/10.1016/j.neurobiolaging.2017.11.008.

Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S and Zhang J. : Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. Neurology. 90(2), Jan 2018 Notes: First published online December 13, 2017, DOI: https://doi.org/10.1212/WNL.0000000000004798

Irwin DJ, Sharon X Xie, Coughlin D, Nevier N, Akhtar R, McMillan CT, Lee EB, Wolk DA, Weintraub D, Chen-Plotkin A, Duda JE, Spindler M, Siderowf A, Hurtig HI, Shaw LM, Grossman M,and Trojanowski JQ. : CSF Tau and Amyloid-Beta Predict Cerebral Synucleinopathy in Autopsied Lewy Body Disorders. Neurology. 90: 1-9, 2018 Notes: DOI: 10.1212/WNL.0000000000005166.

Goldman JG, Andrews H, Amara A, Naito A, Alcalay RN, Shaw LM, Taylor P, Xie T, Tuite P, Henchcliffe C, Hogarth P, Frank S, Dain-Hilaire M-H, Frasier M, Arnedo V, Reimer AN, Sutherland M, Swanson-Fischer C, Gwinn K, Kang UJ. : Cerebrospinal Fluid, Plasma, and saliva in the BioFIND Study: Relationships among biomarkers and Parkinson's disease features. Movement Disorders. 33(2): 282-88, 2018 Notes: Published online 4 December 2017 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.27232

Toledo JB, Arnold M, Kastenmüller G, Chang R, Baillie RA, Han X, Thambisetty M, Tenenbaum JD, Suhre K, Thompson JW, St. John-Williams L, MahmoudianDehkordi S, Rotroff DM, Jack JR, Motsinger-Reif A, Risacher SL, Blach C, Lucas JE, Massaro T, Louie G, Zhu H, Dallmann G, Klavins K, Koal T, Kim S, Nho K, Shen L, Casanova R, Varma S, Legido-Quigley C, Moseley MA, Zhu K, Henrion MYR, van der Lee SJ, Harms AC, Demirkan A, Hankemeier T, van Duijn CM, Trojanowski JQ, Shaw LM, Saykin AJ, Weiner MW, Doraiswamy PM, Kaddurah-Daouk R, for the Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium.: Metabolic network failures in Alzheimer's disease - A biochemical road map. Alzheimer's & Dementia. 13(9): 965-984, Sept 2017 Notes: DOI: https://doi.org/10.1016/j.jalz.2017.01.020.

Caspell-Garcia C, Simuni T, Tosun-Turgut D, Wu I-W, Zhang Y, Nalls M, Singleton A, Shaw LM, Kang J-H, Trojanowski JQ, Siderowf A, Coffey C, Lasch S, Aarsland D, Burn D, Chahine LM, Espay AJ, Foster ED, Hawkins KA, Litvan I, Richard I, Weintraub D, and The Parkinson's Progressive Markers Initiative (PPMI). : Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson Disease. PLOS One 12(5): 1-18, May 2017 Notes: https://doi.org/10.1371/journal.pone.0175674.

Lewczuk P, Riederer P, O’Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack Jr CR, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, etal. : Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. The World J of Biol Psych. 2017 Notes: doi=10.1080/15622975.2017.1375556.

Deters KD, Risacher SL, Kim S, Nho K, West JD, Blennow K, Zetterberg H, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ for the Alzheimer Disease Neuroimaging Initiative. : Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease. 58: 1245-1254, 2017 Notes: Accepted April 13, 2017.

Arneric SP, Batrla-Utermann R, Beckett L, Bittner T, Blennow K, Carter L, Dean R, Engelborghs S, Genius J, Gordon MF, Hitchcock J, Kaplow J, Luthman J, Meibach R, Raunig D, Romero K, Samtani MN, Savage M, Shaw LM, Stephenson D, Umek RM, Vanderstichele H, Willis B, Yule S. : Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. J Alzheimers Disease. 55: 19-35, 2017.

back to top
Last updated: 02/21/2018
The Trustees of the University of Pennsylvania